Dasotraline

Dasotraline
Identifiers

IUPAC name (1R,4S)-4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine
CAS Number	675126-05-3^Y
PubChem CID	9947999
ChemSpider	8123611^N
UNII	4D28EY0L5T
KEGG	D10700^Y
ChEMBL	CHEMBL3301595
Chemical and physical data
Formula	C₁₆H₁₅Cl₂N
Molar mass	292.20 g·mol⁻¹
3D model (Jmol)	Interactive image
SMILES C1C[C@H](C2=CC=CC=C2[C@@H]1C3=CC(=C(C=C3)Cl)Cl)N
InChI InChI=1S/C16H15Cl2N/c17-14-7-5-10(9-15(14)18)11-6-8-16(19)13-4-2-1-3-12(11)13/h1-5,7,9,11,16H,6,8,19H2/t11-,16+/m0/s1 Key:SRPXSILJHWNFMK-MEDUHNTESA-N
^NY (what is this?)

Dasotraline (INN) (former developmental code name SEP-225,289) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) that is under development by Sunovion for clinical use. The drug is no longer being developed for major depressive disorder (MDD), but is still under investigation for the treatment of attention-deficit hyperactivity disorder (ADHD) and eating disorders. Structurally, dasotraline is a stereoisomer of desmethylsertraline, which is an active metabolite of the marketed selective serotonin reuptake inhibitor (SSRI) antidepressant sertraline (Zoloft) and an SNDRI similarly.

In phase I trials for ADHD, test subjects reported the following side effects: